Completed PHASE1 INTERVENTIONAL 4-arm NCT02117362

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Sponsor: Galectin Therapeutics Inc.

Interventions 1 mg/kg GR-MD-02 2 mg/kg GR-MD-02 4 mg/kg GR-MD-02 8 mg/kg GR-MD-02 Ipilimumab

Updated 8 times since 2017 Last updated: Mar 19, 2019 Started: May 8, 2014 Primary completion: Nov 28, 2018 Completion: Nov 28, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Metastatic Melanoma, this trial is completed. The trial is conducted by Galectin Therapeutics Inc. and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE1

▶ Show 3 earlier versions

May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2017 — May 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galectin Therapeutics Inc.
Providence Cancer Center, Earle A. Chiles Research Institute
Providence Health & Services

Data source: Providence Health & Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States